Drugs / V504
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00551187 | Oct 2007 → May 2009 | cervical cancer, human papilloma virus infection, vaginal cancer, vulva cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V504 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00551187 ↗ |
| Modality | Vaccine | “evaluate vaccine immunogenicity and how well the body tolerates V504” NCT00551187 ↗ |